Johnson & Johnson Invests Over $1 Billion in Cell Therapy Manufacturing Facility in Pennsylvania

Johnson & Johnson announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The new facility will expand the company's U.S. manufacturing capacity as it advances its portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.

The advanced manufacturing site will utilize cutting-edge cell therapy technologies to help deliver the company's portfolio of transformational medicines. The facility is designed to support plans to manufacture the vast majority of its advanced medicines in the U.S. to meet the needs of patients in the U.S.

The facility will support more than 500 skilled biomanufacturing jobs when fully operational and more than 4,000 construction jobs during site development. The investment further strengthens the company's longstanding economic impact across Pennsylvania, which totals approximately $10 billion annually.

The announcement is part of the company's previously announced $55 billion U.S. investment in manufacturing, research and development, and technology through early 2029. With ten facilities encompassing more than 2 million square feet dedicated to manufacturing, research, distribution, and office operations, Johnson & Johnson maintains one of the most significant, statewide footprints in the healthcare industry.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It operates through two main divisions: innovative medicine and medtech, following the divestment of its consumer business, Kenvue, in 2023. The company's drug division focuses on immunology, oncology, and neurology, with over half of its revenue generated in the United States.